Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Sings Lyrica's Praises In Beating Earnings Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

Company beats recent lowered earnings guidance as a result of strong performance in its human health division as well as faster-than-anticipated cost savings from restructuring program.

You may also be interested in...

Pfizer’s Great Expectations: Sutent, Exubera Forecasts Exceed Those Of Investors

Firm projects 2010 annual sales of $2 bil. for the inhaled insulin and $1.5 bil. for the oncologic.

Pfizer Launches Lyrica Nine Months After First Approval

Pregabalin gestational period encompassed approval of three indications, DEA scheduling and production of packaging.

NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter

DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts